A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative.
Qian J, Xie Y, Mao Q, Xie Q, Gu Y, Chen X, Hu G, Yang Y, Lu J, Zou G, Zhang Q, Fu L, Chen Y, Guo X, Hou J, Yan Y, Wu JJ, Cui Y, Wang G.
Qian J, et al. Among authors: guo x.
Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001006. Online ahead of print.
Hepatology. 2024.
PMID: 38976867